Introduction {#sec1_1}
============

Basedow disease is an autoimmune disorder and is the most common cause of hyperthyroidism, which is associated with an increased risk for ischemic stroke among young adults \[[@B1]\]. Several underlying mechanisms have been correlated with this phenomenon, which include atrial fibrillation, antiphospholipid syndrome, cerebral vasospasm, cerebral vasculitis, and quasi-moyamoya disease \[[@B2]\]. Basedow disease is rarely accompanied by moyamoya vasculopathy (MMV); therefore, the underlying pathology, treatment, and prognosis of such condition has not been fully elucidated.

Herein, we present a patient who developed recurrent acute ischemic stroke with MMV associated with Basedow disease. The condition was characterized by recurring deterioration and improvement of the intracranial artery stenosis that is dependent on the thyroid hormone status.

Case Report {#sec1_2}
===========

A 31-year-old woman was admitted to our hospital due to sudden weakness in the left upper limb. She had experienced transient weakness in her left hand 7 days earlier and transient numbness in the left side of her face 3 days earlier. No significant findings were obtained based on her medical history, except for appendectomy due to appendicitis at the age of 20 years. She had taken oral contraceptives and smoked two packs of cigarettes a day. Her family history was noncontributory.

Physical examination revealed tachycardia, diffuse goiter, fine finger tremor, and excessive sweating. She was alert and had mild left hemiparesis (manual muscle test: 4/5 in both arms and legs) and left hand hypesthesia. Other neurological examination results were normal. Moreover, complete blood count, serum chemistry, and coagulation test findings were normal. She presented with high levels of free triiodothyronine at 12.30 pg/mL and free thyroxine (fT~4~) at 3.04 ng/dL and low levels of thyroid-stimulating hormone (TSH) at 0.00 µIU/mL. The patient tested positive for thyroid autoantibody including TSH-stimulating antibody, but not for antinuclear antibody and perinuclear and cytoplasmic antineutrophil cytoplasmic antibody.

Electrocardiography, Holter electrocardiography, and transthoracic echocardiography did not show any abnormalities. Thyroid ultrasonography revealed diffuse goiter with hypervascularity. Magnetic resonance imaging (MRI) showed acute cerebral infarctions in the right frontal and parietal lobes (Fig. [1a](#F1){ref-type="fig"}). Magnetic resonance angiography (MRA) revealed stenosis in the proximal portions of the bilateral middle cerebral arteries (MCAs) and the terminal portions of the bilateral internal carotid arteries (ICAs) (Fig. [1b](#F1){ref-type="fig"}, [2a](#F2){ref-type="fig"}). Conventional cerebral angiography using iodine contrast agent was not performed, because the patient presented with thyrotoxicosis. SPECT (single-photon emission tomography) showed decreased cerebral blood flow in the right MCA territory (Fig. [1c](#F1){ref-type="fig"}).

The patient was then diagnosed with acute ischemic stroke with MMV and thyrotoxicosis due to Basedow disease. We administered aspirin and cilostazol orally and argatroban and edaravone intravenously. The use of oral contraceptives was discontinued, and thiamazole and potassium iodide were initiated for the treatment of Basedow disease. Her clinical symptoms disappeared on the 3rd day of hospitalization, and she was discharged from the hospital on the 18th day of hospitalization. The use of medications, such as cilostazol and thiamazole, was continued.

She became euthyroid after 2 months, and MRA showed improvement in intracranial artery stenosis to some extent (Fig. [2b](#F2){ref-type="fig"}). Four months later, further improvement was observed on MRA (Fig. [2c](#F2){ref-type="fig"}), and conventional cerebral angiography showed mild stenosis of MCAs without the presence of moyamoya vessels at the base of the brain. SPECT did not reveal any abnormalities, thereby indicating an improvement in cerebral blood flow in the right MCA territory. Six months later, she developed transient left hemiparesis during the 7th week of gestation. Laboratory test results showed deterioration of thyroid function (fT~4~ level of 1.77 ng/dL and TSH level of 0.00 µIU/mL). MRI did not show any infarctions; however, MRA revealed slight re-stenosis of the bilateral MCAs (Fig. [2d](#F2){ref-type="fig"}). She became euthyroid after 3 weeks and underwent artificial abortion.

After a month of transient ischemic attack, a week after she had become euthyroid, MRA showed progression of bilateral MCA stenosis (Fig. [2e](#F2){ref-type="fig"}), and high-resolution, black-blood T1-weighted MRI with fat suppression did not reveal wall thickening of the stenosed MCAs (Fig. [3](#F3){ref-type="fig"}). MRA after 3 months of transient ischemic attack again showed improvement of the MCA stenosis (Fig. [2f](#F2){ref-type="fig"}).

Discussion {#sec1_3}
==========

This case was characterized by repeated ischemic stroke with progression of MMV during thyrotoxicosis. The patient presented with severe stenosis in the distal ICAs and proximal MCAs, and these angiographic findings corresponded to MMV. We could not perform conventional cerebral angiography during the acute period due to thyrotoxicosis; therefore, the presence of moyamoya vessels was not accurately evaluated. Unexpectedly, intracranial artery stenosis gradually improved after a few months with the treatment of thyrotoxicosis. Moyamoya vessels were not observed on cerebral angiography performed during the chronic period when MMV almost improved. Therefore, we could not make a diagnosis of quasi-moyamoya disease without evidence of moyamoya vessels and used MMV to describe the morphological change of the intracranial arteries in this patient. Notably, the MMV-associated Basedow disease progressed during thyrotoxicosis and improved with normalization of the thyroid hormone status in our case.

Although Basedow disease is rarely complicated by MMV, Basedow-related MMV (Bas-MMV) usually occurs in young women during thyrotoxicosis. Revascularization surgery is occasionally required for Bas-MMV during the acute period of ischemic stroke \[[@B3]\]. However, the prognosis of Bas-MMV has not been fully elucidated, and such a condition may not always progress, unlike moyamoya disease. Table [1](#T1){ref-type="table"} shows a summary of 6 case reports \[[@B4], [@B5], [@B6], [@B7], [@B8], [@B9]\] which showed improvement in Bas-MMV during the clinical course. Three patients (cases 1--3) and the patient in this case report were treated with an antithyroid drug \[[@B4], [@B5], [@B6]\], and 1 patient (case 4) was treated with an antithyroid drug and angioplasty \[[@B7]\]. The remaining 2 patients (cases 5 and 6) were treated with antithyroid and immunosuppressive agents \[[@B8], [@B9]\]. In cases 1--3 and our case, Bas-MMV improved after a few months, and residual stenosis was more likely to be observed \[[@B4], [@B5], [@B6]\]. In case 4, the patient was treated via angioplasty using verapamil during the acute phase of ischemic stroke, and improvement in MMV to some extent was observed. Moreover, the patient completely recovered after 6 weeks \[[@B7]\]. This case shows that Bas-MMV might be at least partially caused by vasospasm. In case 6, methylprednisolone, in addition to an antithyroid drug, was used because wall thickening of the stenotic vessels was observed with gadolinium enhancement \[[@B9]\]. It was assumed that cerebral vasculitis was the underlying pathogenesis in this case.

The pathogenesis of Bas-MMV is not fully understood; however, some mechanisms are associated with this condition. Numerous case reports of coronary artery spasm in Basedow disease are available \[[@B10]\], and the study by Oh et al. \[[@B7]\] has shown that Bas-MMV can also be caused at least in part by vasospasm. It is hypothesized that the activation of sympathetic nerves through hyperthyroidism induces vasospasm. Cerebral arteries are innervated by sympathetic nerves containing noradrenaline and 5-hydroxytryptamine, and excess catecholamine levels or sensitivity due to thyrotoxicosis can lead to vasospasm \[[@B11]\]. Moreover, vascular contractile responses to norepinephrine were greater in large vessels than in small ones \[[@B12]\]. This fact may explain the stenosis in large arteries, such as the ICA or MCA, in Bas-MMV.

However, vasospasm may not fully explain the vascular morphological change in Bas-MMV, because arterial stenosis improved a few months after normalization of the thyroid hormone status, and, subsequently, residual stenosis was usually observed. Gon et al. \[[@B13]\] and Ito et al. \[[@B9]\] have reported that arterial wall thickness in Bas-MMV was observed in imaging studies with gadolinium enhancement. The latter study used methylprednisolone and achieved good recovery of Bas-MMV \[[@B9]\]. Thus, both artery spasm and an immunological mechanism might be associated with morphological change in the cerebral arteries in Bas-MMV; however, further studies must be conducted to accurately determine the etiology.

In our case, oral contraceptives and smoking could have been associated with the first ischemic stroke and pregnancy with the second one. Increased serum estrogen levels due to the use of oral contraceptives or pregnancy can increase the risk of ischemic events. Human chorionic gonadotropin produced during pregnancy also has a thyroid-stimulating effect \[[@B14]\], and it is associated with the progression of Basedow disease. In addition to Bas-MMV, cerebral hemodynamic changes due to thyrotoxicosis might be associated with the occurrence of ischemic stroke \[[@B15]\].

Herein, we presented a patient who developed acute ischemic stroke with progression of Bas-MMV during thyrotoxicosis. The patient almost recovered with normalization of the thyroid hormone status after a few months. Although various mechanisms are associated with this condition, appropriate treatment for Bas-MMV is not fully elucidated. In some cases, patients with Bas-MMV can recover with treatment for thyrotoxicosis. Revascularization surgery should not be considered unless the cerebral artery steno-occlusive lesions remain even after appropriate antithyroid treatment.
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![Magnetic resonance imaging (MRI) and single-photon emission tomography (SPECT) findings during the initial stroke. **a** MRI showed cerebral infarctions in the right frontal and parietal lobes. **b** Left: magnetic resonance angiography revealed stenosis of the proximal portions of the bilateral middle cerebral arteries (MCAs) and the terminal portions of the bilateral internal carotid arteries. Right: SPECT showed decreased cerebral blood flow in the right MCA territory.](crn-0012-0140-g01){#F1}

![Brain magnetic resonance angiography (MRA) during the clinical course. **a** Initial MRA revealed stenosis in the proximal portions of the bilateral middle cerebral arteries (MCAs). **b** Two months later, bilateral MCA stenosis improved to some extent. **c** Four months later, further improvement was observed. **d** Six months later, the patient developed transient left hemiparesis, and slight re-stenosis of MCAs was observed. **e** Seven months later, a week after the patient had become euthyroid, bilateral MCA stenosis worsened. **f** Nine months later, bilateral MCA stenosis improved again.](crn-0012-0140-g02){#F2}

![High-resolution, black-blood fat-suppressed pre-contrast T1-weighted images 7 months after the initial stroke (1 month after the 2nd ischemic event). **a**, **b** Long and short axial images revealing the absence of thickening in the vessel wall of the stenosed middle cerebral arteries.](crn-0012-0140-g03){#F3}

###### 

Summary of 6 case reports which showed improvement in Basedow-related MMV during the clinical course

  Case No.   Ref. No.    Age, years/sex   Symptoms                                    Stroke type   Steno-occlusive lesions   Thyrotoxicosis   Therapy                     2nd angiography (period, finding)      3rd angiography (period, finding)   Residual stenosis
  ---------- ----------- ---------------- ------------------------------------------- ------------- ------------------------- ---------------- --------------------------- -------------------------------------- ----------------------------------- -------------------
  1          4           19/F             headache                                    hemorrhagic   bil ICAs/MCAs/ACAs        \+               AT alone                    1 m, improved                          1 y, further improved               \+
                                                                                                                                                                                                                                                      
  2          5           29/F             transient aphagia, numbness of limbs        ischemic      bil ICAs/MCAs/ACAs        \+               AT, AP                      6 m, improved                          −                                   \+
                                                                                                                                                                                                                                                      
  3          6           26/F             lt hemiparesis                              ischemic      rt ICA/bil ECAs           \+               AT, AP                      6 m, improved                          −                                   NM
                                                                                                                                                                                                                                                      
  4          7           30/F             cortical blindness                          ischemic      bil ICAs/MCAs/ACAs/PCAs   −                AT, angioplasty             2 d, improved                          6 w, recovery                       −
                                                                                                                                                                                                                                                      
  5          8           45/F             consciousness disturbance, rt hemiparesis   ischemic      bil MCAs/ACAs/PCAs        \+               AT, mPSL, plasma pheresis   4 m, improved                          −                                   −
                                                                                                                                                                                                                                                      
  6          9           37/F             paresis of rt arm                           ischemic      none                      \+               AT, mPSL, AP                5 m, TIA, stenosis of lt ICA/MCA/ACA   18 m, improved                      \+
                                                                                                                                                                                                                                                      
  7          this case   31/F             lt hemiparesis                              ischemic      bil ICAs/MCAs             \+               AT, AP                      2 m, improved                          4 m, further improved               \+

ACA, anterior cerebral artery; AP, antiplatelet drug; AT, antithyroid drug; bil, bilateral; d, day(s); ECA, external carotid artery; ICA, internal carotid artery; lt, left; MCA, middle cerebral artery; m, month(s); MMV, moyamoya vasculopathy; mPSL, methylprednisolone; NM, not mentioned; PCA, posterior cerebral artery; rt, right; w, week(s); y, year(s).
